^
    Back
    Association details:
    Biomarker:FGFR2 rearrangement
    Cancer:Cholangiocarcinoma
    Drug:Truseltiq (infigratinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/28/2021
    Excerpt:
    TRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
    Test:
    FoundationOne® CDx
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    06/15/2021
    Excerpt:
    For Cholangiocarcinoma with FGFR2 fusions or rearrangements...Infigratinib
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2021
    Title:

    Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

    Published date:
    01/11/2021
    Excerpt:
    ...cholangiocarcinoma (CCA)...patients, including 83 (77%) with FGFR2 fusions, received infigratinib...Infigratinib is associated with promising anticancer activity and a manageable AE profile in patients with advanced, refractory CCA with an FGFR2 gene fusion or rearrangement.
    Trial ID:
    NCT02150967